INTRODUCTION: G PROTEIN-LINKED RECEPTORS ARE MEMBERS OF A GENE SUPERFAMILY
A large number of neurotransmitters, peptide hormones, neuromodulators, and autocrine and paracrine factors elicit changes in cellular metabolism by interaction with cell membrane receptors that are coupled to intracellular effector enzymes by guanine-nucleotide-binding regulatory proteins (G proteins) (see Table 1 ). While the number of endogenous signalling agents that bind to G protein-coupled receptors is quite large, the number of distinct receptors that mediate their actions is even larger. Among neurotransmitter receptors there exist at least ten types of adrenergic receptors (alA, aclB, alC9 X2A, a2B, a2C, a2D, 1 A2 and /13), at least five types of muscarinic acetylcholine (ml-m5) and dopamine (D1-D5) receptors, and several serotonergic, purinergic, light (rhodopsin) and olfactory receptors. Similarly, among polypeptide hormone receptors the existence of receptor subtypes is well documented.
G protein-mediated transmembrane signalling pathways have generated a great deal of attention because of the many physiological and pharmacological events that are modulated by these mechanisms. G proteins, which are heterotrimeric proteins composed of a, /3, and y subunits, are members of a large gene superfamily (Gilman, 1987; Iyengar & Birnbaumer, 1990 ). In the basal state, the G protein oligomer exists in a complex with GDP; the rate of GDP dissociation from the G protein is extremely slow. Following agonist binding, G protein-coupled receptors undergo one or more conformational changes that trigger receptor-G-protein interactions, facilitating an exchange of GTP for bound GDP at a site within the a subunit of the G protein. The binding of GTP to the a subunit of the G protein promotes dissociation of this subunit from the , and y subunits.
GTP-liganded a subunits (and in some cases, the fy subunits) are responsible for modulating the activity of distinct effector systems, including adenylate cyclase, phospholipases, cyclic GMP phosphodiesterase and ion channels, leading to metabolic and/or ionic changes within the cell. This reaction is terminated by hydrolysis of bound GTP by a GTPase intrinsic to the a subunit, leading to reassociation of Ga with G,/y. The role of the receptor in this system is to serve as a catalyst for the activation of G proteins.
During the past 5 years, more than 100 G protein-coupled receptor subtypes have been cloned and sequenced. This rapid progress has been based in large part on the conservation of primary structure among G protein-coupled receptors, particularly within families, allowing for isolation of new cDNA and genomic clones by cross-hybridization. In addition, the application of new molecular cloning techniques, such as the PCR, has had a major impact on the isolation of G protein-coupled receptor clones. Sequence identity in the regions of the receptor genes coding for transmembrane domains has allowed probes to be generated that hybridize to other members of the family. PCR was first exploited by Libert et al. (1989) to isolate several novel members of the G protein-coupled receptor family, and has subsequently been used to isolate cDNAs for the NK-I (Hershey & Krause, 1990) , (Gerard et al., 1990 ), D1 dopamine ) and histamine H2 (Gantz et al., 1991) receptors, as well as a new subfamily of odorant receptors (Buck & Axel, 1991) .
The visual pigments were the first G protein-linked receptors for which sequence data were obtained. In the early 1980s, the complete amino acid sequences for bovine (Ovchinnikov et al., 1982; Hargrave et al., 1983) and ovine (Pappin et al., 1984) rhodopsin were reported and found to display marked similarities. These sequence data were used to design oligonucleotide probes and clone the genes encoding bovine and human opsins (Nathans & Hogness, 1983 . When the gene encoding a mammalian /,-adrenergic receptor (Dixon et al., 1986 ) was subsequently cloned, it was apparent from the deduced sequence that this receptor exhibited a structure similar to that of the rhodopsins, and suggested the existence of a family of signal receptors.
Current models for the secondary and tertiary structure of G protein-linked receptors are based in large part on the known folding patterns of the ancient retinal-linked visual pigment, bacteriorhodopsin, that is found in naturally occurring lattices within the purple membranes of Halobacterium halobium. This pigment, which acts as a proton pump, is not linked to any G protein (Khorana, 1988) . When analysed by electron microscopy and high resolution electron diffraction, bacteriorhodopsin is seen as seven a-helices, arranged in a bundle perpendicular to the plane of the lipid bilayer (Henderson & Unwin, 1975; Engelman et al., 1980; Henderson et al., 1990) . The basic features of this model are depicted in Fig. 1 . Mutagenesis data have supported the idea that the helices are oriented with their hydrophobic faces pointing out into the membrane lipids and their hydrophilic faces point in to the active sites on the molecule (see below).
Comparison of the deduced amino acid sequences ofG proteincoupled receptors reveals a similar secondary structure: a single polypeptide chain containing six relatively hydrophobic domains plus a seventh region of lower hydrophobicity. These domains display sequence similarity among most receptor classes and marked similarities among receptor subtypes. Since the seven hydrophobic domains in each receptor are similar in size (20-28 amino acids) and of sufficient length to span the lipid bilayer, they have been postulated to form membrane-spanning domains. The intervening sequences, which are considerably more hydrophilic and display greater sequence diversity, form domains that are exposed intracellularly and extracellularly. The N-terminal sequence of most G protein-coupled receptors contains putative sites for N-linked glycosylation (Asn-Xaa-Ser/Thr) and is presumed to be located extracellularly (Fig. 2) . This model places the C-terminus of the receptors intracellularly. Studies on the topography of rhodopsin (Applebury & Hargrave, 1986 , and references therein) and the /?2-adrenergic receptor (Wang et al., 1989) support this model for the orientation of G protein receptors in the plasma membrane.
A more detailed comparison of the amino acid sequences of G protein-coupled receptors reveals that they share a number of conserved amino acids or domains (Fig. 3) . Some of the more conserved residues among members of this gene family include two extracellular cysteine residues that have been shown to form a disulphide linkage in rhodopsin and the muscarinic receptor (Karnik et al., 1988; Curtis et al., 1989; Kurtenbach et al., 1990) , proline residues in helices IV, V, VI and VII, an asparagine in helix I, a leucine in helix II and an arginine in helix III. Atwood et al. (1991) noted that conserved polar residues contained within the transmembrane domains were always positioned on the internal side of the helices, and all but one of the conserved aromatic residues were located on external faces of the helices. It was speculated that the strictly conserved residues play an essential role in maintaining the structure of the receptor, perhaps by determining protein folding, whereas those residues conserved only among major classes of receptors may play a role in defining The tertiary structure is shown of bacteriorhodopsin in the purple membrane obtained by Henderson et al. (1990) . The transmembrane a-helices (in red) are labelled A-G. Illustrated on the figure are several conserved aspartic acid residues that have been implicated in the proton pumping mechanism of bacteriorhodopsin. their unique functional properties (Atwood et al., 1991) . Conservation of structural and/or functional domains suggests that G protein-coupled receptors may have a common ancestry. It is interesting that genes encoding certain adrenergic receptor subtypes are clustered in the genome de [-5-16~~~~~~l e lel61-63-0 deld239-3272. Highlighted on this schematic diagram of the human /12-adrenergic receptor are several key amino acids and domains that have been studied using mutagenesis techniques. The amino acid sequence of the receptor is given by the single letter code. The pink area in the middle of the figure represents the plasma membrane; the areas above and below the membrane represent the extracellular and intracellular space, respectively. The proposed structure of the /J2-adrenergic receptor consists of seven hydrophobic regions spanning the membrane forming extracellular and intracellular loops. The N-terminus of the receptor is located extracellularly and the C-terminus is located intracellularly.
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by mutagenesis may change its biochemical reactivity or produce an unfavourable structural perturbation. Thus one would ideally like to support data obtained from mutagenesis studies with biochemical techniques and vice versa. The use of in vitro mutagenesis to study structure-function relationships in G protein-coupled receptors is relatively recent. It is the purpose of this review to compile and assess the evidence that has been obtained to date. Although there are many gaps in our knowledge, we have tried to emphasize mutagenesis studies on those residues that are present in the majority of G proteinlinked receptors, with the hope of identifying some common structure-activity relationships among these proteins. Elucidation of the mechanisms of receptor activation and G protein interactions will continue to be formidable tasks, at least in the near future. In spite of their limitations, mutagenesis studies can at least provide helpful insights into such problems, and can inspire hypotheses that provide directions for continued investigations.
THE SEARCH FOR FEATURES COMMON TO G PROTEIN-COUPLED RECEPTORS Structural features involved in ligand binding
One of the major functions of most G protein-coupled receptors is to recognize specific hormones/regulatory molecules present in the extracellular environment. The opsins are exceptional is this regard in that their 'ligand', the retinal chromophore, is covalently bound to the apoprotein. Since each receptorligand interaction is highly specific, it seems intuitive that each receptor has evolved unique structural elements for ligand recognition.
Much of the evidence obtained to date would suggest that the membrane-spanning regions of G protein-coupled receptors are involved in ligand binding. This concept has its origins in physical studies on bacteriorhodopsin. The all-trans-retinal chromophore of bacteriorhodopsin is attached via a Schiff base to Lys216, located in the seventh transmembrane helix of the protein (Bayley et al., 1981; Mullen et al., 1981) , and is contained within a pocket formed by the transmembrane helices (Henderson et al., 1990; see Fig. 1 ). Similarly, the 1 1-cis-retinal chromophore of the visual pigments is covalently attached to Lys296 located in transmembrane helix VII of bovine rhodopsin Findlay et al., 1981) , and is believed to interact with residues on the core-facing surface of one or more helices (Applebury & Hargrave, 1986) . It has been speculated that, by analogy, the seven a-helices of G protein-coupled receptors may also form a ligand-binding pocket Venter et al., 1989 . The Cterminus also appears to play little or no role in ligand binding, as mutations that result in the truncation of large portions of this region in hamster and human (Kobilka et al., 1987c) /32-adrenergic receptors do not alter their binding properties. Taken together, these data suggest that the hydrophilic portions of the fl-adrenergic receptor do not play a significant role in ligand binding [83] [84] [85] [86] [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] as the site of label incorporation (Dohlman et al., 1988 (Wong et al., 1988 (Tota & Strader, 1990) . Evidence has suggested that one or more conserved transmembrane aspartate residues may play a role in catecholamine binding (see Fig. 4 ). Substitution of Asp"13 in transmembrane helix III of the hamster /J2-adrenergic receptor with asparagine or glutamate greatly decreased the ability of the receptor to bind
[1251]ICYP, dihydroalprenolol and other antagonists (Strader et al., 1989c and human Chung et al., 1988 (Wang et al., 1991) , ml muscarinic receptors (Fraser et al., 1989b) and D2 dopamine receptors (Neve et al., 1991) (Strader et al., 1989a,b peptide, Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-GluPro-Phe, which mimics the new N-terminus created by thrombin action, acted as a potent thrombin receptor agonist. Significantly, this peptide was equally efficacious in activating the cleavageresistant mutant thrombin receptors containing Ala41 and Pro42. It has been proposed that thrombin recognizes the Leu-Asp-ProArg-Ser sequence and that cleavage of the Arg-Ser peptide bond generates a new N-terminus which acts as a 'tethered' ligand to trigger receptor activation (Vu et al. 1991a) . Follow-up studies demonstrated that a highly anionic domain located within the Nterminus and distal to the thrombin cleavage site participates in the recognition of thrombin, as deletion of this region (positions 51-63) caused a 100-fold shift to the right in the ability of thrombin to trigger receptor activation (Vu et al., 1991b (Lucas et al., 1978; Vauquelin et al., 1979; Aronstam & Eldefrawi, 1979; Abd-Elfattah & Shamoo, 1981; Pederson & Ross, 1985; Moxham et al., 1988 , Berstein et al., 1988 , cysteine residues have been the subject of considerable investigation using mutagenesis and biochemical techniques. The majority of G protein-coupled receptors sequenced to date contain a pair of conserved cysteine residues in the second and third extracellular domains (see Fig. 3 The numbering and putative locations of these conserved aspartates are depicted using a model of the rat ml muscarinic acetylcholine receptor.
Note the putative sites of N-glycosylation within the extracellular amino terminus (Y), the regions of a-helices (coils) and the sites of charged residues (-or +). The sequence data are from the following sources: rat m1-m5 muscarinic receptors (Kubo et al., 1986a,b; Gocayne et al., 1987; Bonner et al., 1987 Bonner et al., , 1988 Liao et al., 1989) ; hamster al-adrenergic receptor (Cottechia et al., 1988) ; human a2-adrenergic receptor (Kobilka et al., 1987b) ; human fl1adrenergic receptor (Frielle et al., 1987) ; human f82-adrenergic receptor (Chung et al., 1987; Kobilka et al., 1987a) ; turkey ,Badrenergic receptor (Yarden et al., 1986) ; rat D2 dopamine receptor (Bunzow et al., 1988) ; rat 5HTl c 5-hydroxytryptamine receptor (Julius et al., 1988) ; human 5HT1A 5-hydroxytryptamine receptor (Fargin et (Karnik & Khorana, 1990 Fig. 2 ) to valine causes a complex shift in the agonist-binding properties of the mutant receptors (Savarese et al., 1990) . It remains to be determined if these mutations directly affect ligand binding, or alter the processing of the protein and/or its insertion into the plasma membrane.
However, it appears that the role of the conserved extracellular cysteines in muscarinic and fl-adrenergic receptors may not be identical, as mutant fl-receptors lacking either of these residues are transported to the membrane and retain the ability to bind ligands, in contrast to the findings with the muscarinic receptor.
There are examples of G protein-coupled receptors that lack a cysteine residue in the second extracellular loop, including the human mas oncogene (Young et al., 1986 ) which reportedly encodes a receptor for the angiotensins (Jackson et al., 1988) and the rat cannabinoid receptor (Matsuda et al., 1990 Light-induced activation of bacteriorhodopsin involves ionic movements across the cell membrane through a series of charged residues. Absorption of light by the all-trans-retinal chromophore triggers a photochemical cycle in which the chromophore is converted to 13-cis-retinal; during this cycle the Schiff base formed by attachment of the retinal to Lys216 of bacteriorhodopsin undergoes protonation and deprotonation (Khorana, 1988) . This photochemical cycle drives the translocation of protons from inside to outside the cell, creating an electro-chemical gradient that is utilized by the cell for ATP synthesis (Findlay & Pappin, 1986) .
Aspartate residues in the transmembrane domains of bacteriorhodopsin (see Fig. 1 ) have been shown to play a critical role in the proton pumping process. Site-directed mutagenesis studies (Mogi et al., 1988) have shown that replacement of Asp86 or Asp96 (both located in transmembrane helix III) by asparagine nearly abolishes the ability of bacteriorhodopsin to translocate protons. Conversion of another aspartate, Asp212 (transmembrane helix VII), to either asparagine or glutamate also results in a decreased proton pumping capacity (-10 and 20 % respectively of that of wild-type receptors). Together, these data suggest that these three aspartate residues are involved in a proton conductance mechanism in bacteriorhodopsin. This hypothesis is supported by an atomic model of the structure of Halobacterium halobium bacteriorhodopsin that has been recently obtained by Henderson etal.(1990) using high resolution electron cryomicroscopy.
The role of negatively charged amino acids in the activation mechanism of the G protein-linked mammalian visual pigments is less well understood. It has been speculated that one or more negatively charged amino acids, presumably at or near the putative core of the pigment protein, may serve as a counterion for the 1 -cis-retinal chromophore, which exists as a protonated Schiff base (Oseroff & Callender, 1974) bound to a lysine moiety within the seventh transmembrane helix (Applebury & Hargrave, 1986) . It is this interaction that accounts for the difference in the absorption maximum of the free protonated retinylidene Schiff base in methanol compared with that of rhodopsin, the fact that different visual pigments containing the same chromophore have varying absorption maxima, and is presumably important in the light-induced receptor activation mechanism. Several independent studies employed site-directed mutagenesis of charged amino acid residues located at or near the transmembrane domains of bovine rhodopsin to determine if they serve as the counterion for the protonated chromophore. Two of these studies found that conversion of Glu"3, which (depending on the model used) is located in either the second extracellular loop or the third transmembrane domain, to glutamine shifted the absorption maximum of this protein from 500 nm to 380 nm (Sakmar et at., 1989; Zhukovsky & Oprian, 1989) . Conversion of other potential counterions, such as Asp83 (second transmembrane domain), Glu'22 (third transmembrane domain) and Glu'34 (third transmembrane domain) to neutral amino acids caused either small or no spectral shifts (Sakmar et at., 1989; Zhukovsky & Oprian, 1989; Nathans, 1990) . These findings suggested that Glu"13 is the counterion for the protonated retinylidene Schiff base in bovine rhodopsin (Sakmar et at., 1989; Zhukovsky & Oprian, 1989) . However, Janssen et at. (1990) reported that the Glnl" bovine rhodopsin did not display spectral characteristics that were markedly different from those of the native protein; the reason for this discrepancy is not apparent. Another issue that has to be considered is that some invertebrate visual pigments lack a negatively charged amino acid in this position. Further work is needed to clarify the role of individual amino acids of the opsin apoprotein in spectral tuning.
2. Aspartate residues and activation of G protein-coupled receptors. A working hypothesis of agonist-induced receptor activation (Venter et (Limbird, 1984) . When Asp79 of the porcine a2-adrenergic receptor is converted to asparagine, the allosteric effects of Na+ ions are completely abolished, suggesting that Nal ions may bind to the carboxylate moiety of this aspartate to induce the allosteric modulation (Horstman et at., 1990) . In another G1-linked receptor, the rat D2 dopamine receptor, substitution of Asp80 with either alanine or glutamate greatly diminishes the ability of this receptor to inhibit adenylate cyclase activity (Neve et at., 1991) . These substitutions also markedly reduce the sensitivity of the D2 dopamine receptor to NaN ions, which in the 100 mm range increase receptor affinity for 1992 substituted benzamide antagonists such as epidepride (Neve et al., 1990) . It has been proposed that D2 receptors undergo a monovalent-cation-dependent isomerization that is important for both ligand affinity and receptor activation, and that the interaction of monovalent cations with Asp8O is crucial for these conformational events (Neve et al., 1991) .
Domains involved with coupling to G proteins: cytoplasmic domains as potential sites for receptor-G protein interactions
One might predict a priori that the cytoplasmic domains of G protein-coupled receptors would be the site(s) of receptor-G protein interactions. Because this family of receptors collectively interacts with a number of distinct G proteins, it seems plausible that the site(s) for receptor-G protein interactions might be located in regions that contain relatively non-similar sequences. The amino acid sequences of the first and second cytoplasmic loops of G protein receptors are relatively conserved, and as such are not attractive as potential sites for determining receptor-G protein specificity . Instead, attention has focused on the third cytoplasmic loop (between transmembrane helices V and VI) and the C-terminus, which display a greater degree of sequence and size heterogeneity among and within these receptor gene families.
However, an argument for the involvement of other cytoplasmic domains of G protein receptors in receptor-G protein coupling can be made, based on theoretical grounds. Weiss et al. (1988) have pointed out that although the opsins have a minimal putative third cytoplasmic loop, rhodopsin is capable of activating purified preparations of a variety of G proteins, such as GC and G0, in functional reconstitution assays (Tsai et al., 1987) . G.
has been shown to associate with a2-adrenergic and m2 muscarinic acetylcholine receptors, which possess relatively large third cytoplasmic loops. Thus the implication is that much of the third cytoplasmic loop of adrenergic and muscarinic receptors has little to do with G protein recognition.
1. p-Adrenergic receptors. Several mutants of the hamster 32-adrenergic receptor with deletions in the putative third cytoplasmic loop have been described that have markedly decreased abilities to stimulate adenylate cyclase. Receptors containing deletions of residues 239-272, representing almost two-thirds of the third cytoplasmic loop (see Fig. 2 ), were unable to activate adenylate cyclase when expressed in L cells . Further studies revealed that the ability of the receptor to stimulate adenylate cyclase could be virtually eliminated by deletion of a relatively short segment in this loop, residues 222-229 . A third deletion mutant (residues 258-270), had a greatly diminished ability to activate adenylate cyclase . As evidence that these deletions result in receptors that are uncoupled from GS, none of these three mutant receptors showed a significant shift to the right in ['25I]ICYP/isoprenaline competition binding curves in the presence of the GTP analogue guanosine 5'-[(/y-imido]triphosphate . In addition, Cheung et al. (1989) showed that one of the mutant receptors which does not activate adenylate cyclase, del-222-229, does not undergo sequestration upon prolonged exposure to isoprenaline, whereas mutants that stimulate adenylate cyclase, even with low efficacy, such as del-258-270, are sequestered at rates comparable with that of wildtype,/2-adrenergic receptors. Finally, a mutagenesis study on the human fl2-adrenergic receptor identified a seven-amino-acid segment (residues 267-273) in the C-terminal end of the third cytoplasmic loop whose deletion results in a receptor that can activate adenylate cyclase with an efficacy of only 50% (Hausdorff et al., 1990 (Fraser et al., 1989a) ; this observation obfuscates any conclusions that can be drawn about G protein binding sites based on a2/fi2-adrenergic receptor chimeras. Asp130, a highly conserved residue located at the interface between transmembrane helix III and the N-terminal end of the second intracellular loop in the human fl2-adrenergic receptor (see Fig. 2 ), appears to be critical for proper G protein coupling. Conversion of this Asp to Asn virtually abolishes the ability of the receptor expressed in B-82 cells to activate adenylate cyclase . Because this residue is located within or very near to the cytoplasm, it is tempting to speculate that the presumptive conformation shifts which occur upon receptor activation may expose, or alternatively mask, the carboxylate side chain of Asp'30, thus altering the interaction of the receptor with G.. Consistent with this hypothesis is the finding that when the corresponding residue in bovine rhodopsin, Glu'34, is reversed with its neighbouring residue, Arg33, the mutant rhodopsin is unable to bind to transducin (see below ; Franke et al., 1990 ).
However, when the analogous aspartate in the rat ml muscarinic acetylcholine receptor, Asp'22, is substituted with Asn, the efficacy of the mutant receptor for activating PI hydrolysis is not diminished, although agonist potency is reduced (Fraser et al., 1989 b) . A similar shift to the right in the dose-response curves for agonist-mediated inhibition of adenylate cyclase has recently been reported for the Asn130 mutant 'X2-adrenergic receptor (Wang et al., 1991) . Thus this locus may be important for receptor coupling to some, but not all, G proteins. O'Dowd et al. (1988) (Ovchinnikov et al., 1988) , conversion of both of these residues to serine produced a mutant rhodopsin capable of activating transducin at a level comparable with the wild-type protein (Karnik et al., 1988) . A potential consensus sequence for palmitoylation, Leu-(Xaa)-Cys-(Xaa).-(Arg/Lys)-has been proposed (Strittmatter et al., 1990 ). This sequence (or portions of it) is found in many, but not all, G protein-coupled receptors, with the critical cysteine residue located 11-16 residues distal to the end of transmembrane helix VII (see Fig. 3 ). Future studies with other receptors in this family will better elucidate the role of palmitoylation in receptor function. To identify regions within this domain of thea1-adrenergic receptor that are responsible for G protein interactions, shorter stretches of sequence in this loop were substituted with those from the human fl2-adrenergic receptor. One substitution, in which Thr-Leu-Arg-Ile-His-Ser-Lys-Asn (residues 252-259 of thea1-adrenergic receptor, near the middle of the thirdintracellular loop) was replaced with Glu-Gly-Arg-Phe-His-ValGln-Asn, resulted in a receptor whose ability to active PI hydrolysis in response to noradrenaline was reduced by 90 %. Unexpectedly, replacement of residues 288-294 in the aladrenergic receptor (Arg-Glu-Lys-Lys-Ala-Ala-Lys, at the Cterminal end of the third intracellular loop) with the sequence Lys-Glu-His-Lys-Ala-Leu-Lys produced a receptor that displayed a 100-fold higher affinity for noradrenaline than did the wild-type a1-adrenergic receptor, and a 300-fold increase in potency for activatingPI breakdown. Since this substitution was relatively conservative, involving only three amino acid mutations (Arg288 to Lys, Lys290 to His and Ala293 to Leu), each of these point mutations was analysed individually. Both theHis290 and Leu293 mutant a -adrenergic receptors had markedly decreasedKi values for noradrenaline and increased potency for activation of PI turnover relative to the wild-type receptor. These mutants also displayed higher basal inositol phosphate levels, leading to the speculation that these point mutations in some way lock the receptor into its active conformation .
The N-terminal portion of the cytoplasmic tail may also be important for acl-adrenergic receptor-G protein coupling. Substitution of a 13-amino-acid segment (positions 353-365) of the hamster a a irenergic receptor, including the cysteine residue that may serve as a site of palmitoylation, with the corresponding sequence of the human fl,2-adrenergic receptor produced a receptor whose capacity for activating phospholipase C was impaired by 40% ).
3. o2A-Adrenergic receptors. A recent study by Dalman & Neubig (1991) utilized six peptides derived from various cytoplasmic domains of the z2A-adrenergic receptor to probe receptor-G protein interactions. Two peptides from (a) the second cytoplasmic loop (peptide A; Gln-Ala-Ile-Glu-Tyr-AsnLeu-Lys-Arg-Thr-Pro-Arg) and (b) the C-terminal end of the third cytoplasmic loop (peptide Q; Arg-Trp-Arg-Gln-Arg-GlnAsn-Arg-Glu-Lys-Arg-Phe-Thr) were potent inhibitors of agonist binding to the receptor; this inhibitory effect was abolished in the presence of guanine nucleotides. Peptide Q also inhibited agonist-stimulated GTPase activity, suggesting that it could mimic the receptor and bind directly to Gi to prevent coupling to the receptor. The interaction of peptide A with the receptor and G protein was distinct from that of peptide Q, as it did not prevent receptor-mediated activation of the G protein.
Together, these data suggest that both the second cytoplasmic loop and the C-terminal portion of the third cytoplasmic loop of thea2A-receptor are involved in the interaction with Gi.
4. Rhodopsin. Takemoto et al. (1985) tested a number of synthetic peptides, 5-9 amino acids in length, corresponding to various putative cytoplasmic regions of bovine rhodopsin, including the C-terminal tail and the three cytoplasmic loops, for their ability to inhibit activation of exogenous transducin by rodouter-segment disc membranes that had been depleted of transducin. Three peptides, corresponding to bovine rhodopsin residues 333-339, 324-331 and 317-321, all located in the Cterminus, were able to block transducin activation, as reflected by a decrease in transducin-catalysed GTPase activity. The peptide corresponding to amino acids 333-339 was the most potent inhibitor among these. Peptides corresponding to the last eight residues on the C-terminus, and the three cytoplasmic loops, failed to block transducin activation in this system. These investigators concluded that residues 317-339 may be the recognition site on rhodopsin for transducin. This domain, however, does not appear to be highly conserved among the opsins. Furthermore, removal of the last 12 amino acids of the Cterminus by proteolysis was shown to have little effect on the ability of transducin to bind to rhodopsin (Kuhn, 1984) .
In contrast, Franke et al. (1988 Franke et al. ( , 1990 found evidence that both the second and third cytoplasmic loops of bovine rhodopsin may be involved in transducin recognition and activation. These investigators created three mutant bovine rhodopsins that lacked the ability to stimulate light-induced GTPase activity associated with transducin (Franke etal., 1990) . The first mutant involved a reversal of the charge pair Glu134/Arg'35, located at the Nterminal end of the second intracellular loop, to Arg 34/Glu'3 . This mutant failed to bind transducin, suggesting that these residues directly participate in the binding reaction or are essential for the correct conformation of the transducin-binding site. Two other mutant rhodopsins, one in which the sequence Cys-LysPro-Met-Ser-Asn-Phe-Arg-Phe-Gly-Glu-Asn-His within the central region of the second intracellular loop is replaced with Gly-Thr-Glu-Gly-Pro-Asn-Phe-Tyr-Val-Pro-Phe-Thr-Ser, and another in which 13 amino acids from residues 237 to 249 in the middle of the third intracellular loop are deleted, can bind transducin but fail to release this G protein in the presence of GTP. It was speculated that these mutant opsins can trigger the release of bound GDP from transducin, but cannot induce the formation of the GTP-binding site within the G protein, leading to an inactive opsin-transducin complex (Franke et at., 1990) . The last mutant is of interest since it corroborates an earlier sitedirected mutagenesis study in which LyS248 of bovine rhodopsin was substituted with Leu (Franke et at., 1988) . This mutation produced a rhodopsin that was completely unable to activate transducin, as monitored by GTPase activity. A lysine residue equivalent to Lys248 has been found in all visual pigments sequenced to date, except for the human blue pigment, which contains an arginine (Nathans et al., 1986) . Interestingly, a comparable residue is present among the f-adrenergic receptors. However, if a triple mutant is created in which the two glutamate residues adjacent to Lys248 are also mutated to neutral amino acids (i.e., -Glu247-Lys248-Glu249-to -Gln247-Leu248-Gln249_), the ability of the receptor to activate transducin-mediated GTPase activity is restored (Franke et al., 1988) . This finding tempers the simplistic postulate that a electrostatic interaction between the positively charged Lys248 and transducin governs rhodopsintransducin dynamics.
A unique approach to the question of rhodopsin-transducin interactions was taken by Hamm et al. (1988) . A series of peptides derived from the sequence of the a subunit of transducin were studied for their ability to compete with transducin for binding to rhodopsin, and to induce conformational changes within rhodopsin that mimic those which occur upon interaction with transducin. Two regions near the C-terminus of the ac subunit of transducin, Glu311-Val328 and Ile340-Phe350, were able to block the binding of transducin to rhodopsin and stabilize the activated form of rhodopsin. Further studies showed that a cysteine at position 321 of the first peptide was required for these effects. This strategy has general utility because, by defining the amino acid residues on any given G protein that are responsible for its interaction with a receptor, one may develop a better understanding of the nature of the molecular mechanisms that govern interaction of these proteins.
Muscarinic acetylcholine receptors. Several studies have
focused on identifying domains within muscarinic acetylcholine receptors that are responsible for G protein interactions. Kubo et al. (1988) created receptor chimeras of ml and m2 subtypes, exchanging their respective third intracellular loops. Normally the ml subtype, which activates PI turnover, can open a Ca2+-dependent ion channel, whereas the m2 subtype cannot. Chimeric m. receptors possessing the third intracellular loop of the m2 subtype, however, were unable to stimulate current; conversely, chimeric m2 receptors possessing the third intracellular loop from the ml subtypes were able to mediate this effect. It was concluded that the third intracellular loops of these receptors determine receptor G protein specificity (Kubo et al., 1988) . Similar results were obtained by Wess et al. (1990) in studies with chimeras of human m2 and rat m3 muscarinic acetylcholine receptors. It was noted, however, that the maximal functional responses mediated by the chimeric receptors were quantitatively far lower than those produced by the corresponding native m2 and m3 receptors. It was concluded that there may be other domains in addition to the third intracellular loop that are necessary for complete G protein coupling. Alternatively, it is possible that the large stretches of' foreign' sequences introduced into these receptors take on a conformation that is significantly different from the conformation that would be taken by the native sequence, resulting in receptors which cannot couple in a maximally efficient way (Wess et al., 1990) .
To identify more precisely the regions within the third intracellular loop of muscarinic receptors that may confer G protein coupling specificity, other studies focused on a 16-17-amino-acid region at the N-terminal end of this loop (i.e. the amino acids of the loop adjacent to the end of transmembrane helix V) (Wess et al., 1989) . Analysis of all muscarinic subtypes revealed that the sequence in this segment is highly conserved amonginl, M3 and m5 muscarinic acetylcholine receptors, i.e.
those that activate phospholipase C, but is distinct from the corresponding segment of the m2 and m4 muscarinic acetylcholine Vol. 283 receptors, i.e. those that inhibit adenylate cyclase, the latter having their own conserved sequence. An m2 chimeric receptor containing the 17-amino-acid stretch from the N-terminal end of the third intracellular loop of the m3 receptor behaved like the wild-type m3 muscarinic acetylcholine receptor, in that it triggered an increase in PI hydrolysis in response to carbachol, albeit with a high EC50 value. In addition, the m3 muscarinic acetylcholine receptor chimera containing the corresponding 16-amino-acid sequence from the m2 receptor lost its capacity for activating PI hydrolysis (Wess et al., 1989 (Wess et al., , 1990 . Thus it appears that this 16-17-amino-acid sequence at the N-terminal end of the third intracellular loops of the m2 and m3 muscarinic acetylcholine receptors may play a key role in determining the ability of these receptors to couple to the G protein(s) that activate phospholipase C. However, this region is apparently not the only determinant of coupling selectivity, since the m2 chimeric receptor which contains the 17-amino-acid stretch from the m3 receptor retains its ability to inhibit adenylate cyclase, whereas the m2 chimeric receptor possessing the entire third intracellular loop of the m3 receptor does not (Wess et al., 1990) . It is of note that deletion of up to 123 of the 156 amino acids of the central portion of the third intracellular loop of the mouse ml muscarinic acetylcholine receptor can be carried out without decreasing the coupling of the receptor to PI turnover (Shapiro & Nathanson, 1989) , supporting the hypothesis that the membrane-proximal sequences of this loop are determinant(s) of G protein specificity.
Different results were obtained by Wong et al. (1990) , who constructed chimeras in which the second or third intracellular loops, or portions thereof, of the human ml muscarinic acetylcholine receptor were substituted with the analogous sequences derived from the turkey /1-adrenergic receptor. It was found that virtually the entire third intracellular loop of the ml receptor (residues 211-364) could be replaced with the corresponding /3-adrenergic sequence without a loss in the ability of the receptor to stimulate PI turnover. Replacement of the second intracellular loop of the ml receptor with the ,-adrenergic receptor sequence also did not diminish the receptor efficacy for activation of phospholipase C. However, replacement of both the second and third intracellular loops resulted in a 75 % reduction in maximal PI turnover; this suggested that these intracellular loops interact in some manner to determine G protein specificity (Wong et al., 1990) .
Domains that undergo post-translational modification 1. N-Glycosylation of the N-terminus. The majority of G protein-coupled receptors sequenced to date contain one or more consensus sequences for N-glycosylation of asparagine residues [Asn-Xaa-(Ser/Thr)] clustered within the extracellular N-terminus (Fig. 3) . In fact, it has been noted that the N-termini of members of the opsin family have no conserved sequences other than two or more canonical N-glycosylation sites (Applebury & Hargrave, 1986) ; the same is true for the five muscarinic acetylcholine receptor subtypes (Bonner, 1989) .
Glycosylation of the N-terminus of several G protein-coupled receptors has been confirmed using biochemical and/or genetic approaches. Hargrave (1977) sequenced a 16-residue trypsin fragment corresponding to the N-terminus of bovine rhodopsin which contained two glycosylated asparagine residues, Asn2 and Asnl5. Dohlman et al. (1987) showed that a carboxypeptidase Y fragment containing the N-terminus of the hamster lung /82-adrenergic receptor was sensitive to a stepwise digestion with endoglycosidase F, suggesting that at least two potential sites, presumed to be Asn6 and Asnl5, were N-glycosylated. More recently, Rands et al. (1990) used site-directed mutagenesis to definitively identify Asn6 and Asn16 as glycosylation sites in the hamster ,l2-adrenergic receptor. A series of mutant receptors was created in which one or both asparagine residues were converted to glutamine, or both potential N-glycosylation sites were removed by deletion mutagenesis (deletion of residues 6-15). (Rands et al., 1990) .
In a parallel study, van Koppen & Nathanson (1990) There are examples of G protein-linked receptors that lack consensus sequences for N-linked glycosylation, in either their N-termini or their extracellular loops. For example, both human (Weinshank et al., 1990) and rat (Zeng et al., 1990) a2B-adrenergic receptors, which lack N-glycosylation consensus sequences, have been expressed in mammalian cells and display the expected pharmacological properties. Also, the RDC8 clone (Libert et al., 1989) , identified as an adenosine A2 receptor (Maenhaut et al., 1990) (Sibley et al., 1986) . A related event, usually occurring on a longer time scale (minutes to hours), is down-regulation, in which the total number of receptors is decreased. In this case, the reappearance of receptors at the cell surface requires new protein synthesis. Below are reviewed some of the molecular events associated with desensitization, and the evidence implicating certain domains of G protein-linked receptors in these processes.
(a) Rhodopsin. It has been known since the early 1970s that rhodopsin undergoes a light-dependent, ATP-dependent phosphorylation (Kuhn & Dreyer, 1972; Bownds et al., 1972; Frank et al., 1973) . The enzyme responsible for this activity, rhodopsin kinase, utilizes only the photoactivated form of rhodopsin as a substrate (Weller et al., 1975; Frank & Buzney, 1975; Kuhn, 1978; Shichi & Somers, 1978) . Protein mapping studies indicated that rhodopsin is phosphorylated at multiple serine and threonine sites clustered in the C-terminus Barclay & Findlay, 1984; Thompson & Findlay, 1984) ; up to 9 mol of phosphate have been reported per mol of pigment (Wilden & Kuhn, 1982) . Phosphorylation of rhodopsin has been proposed to have a signal-terminating function; this was suggested when it was found that addition of ATP to rod outer segments attenuated the activation ofcyclic GMP phosphodiesterase in this system (Liebman & Pugh, 1980) . Furthermore, Miller & Dratz (1984) demonstrated that removal of most of the phosphorylation sites on rhodopsin by proteolytic cleavage of the C-terminus prevented the ATP-dependent deactivation of cyclic GMP phosphodiesterase.
It was subsequently discovered that a 48000 Da protein intrinsic to rod outer segments is capable of binding to phosphorylated, photoactivated rhodopsin. This protein, known as arrestin, mediates the quenching of phototransduction . Arrestin binding to phosphorylated rhodopsin acts to block the binding and activation of transducin, and can almost completely suppress the ability of the receptor to activate phosphodiesterase (Wilden et al., 1986) . It is thought that the sites on rhodopsin for binding of transducin and arrestin may overlap (Wilden et al., 1986) . Arrestin binding to rhodopsin also blocks the additional phosphorylation of rhodopsin by rhodopsin kinase (Buczylko et al., 1991) and interferes with the dephosphorylation of rhodopsin by protein phosphatase 2A (Palczewski et al., 1989) . The net effect of these actions is to facilitate the continued association between phosphorylated rhodopsin and arrestin. Regeneration of the functional phototransduction pathway is dependent on the slow release of arrestin from rhodopsin.
(b) fl-Adrenergic receptors. Certain elements of fl-adrenergic receptor desensitization are analogous to those of the rhodopsin system. Initial studies on ,-adrenergic receptor desensitization indicated that the receptors undergo phosphorylation as a result of prolonged exposure to agonists (Stadel et al., 1983; . In a series of studies, Benovic et al. (1986 Benovic et al. ( , 1987b characterized one of the enzymes responsible for this phosphorylation, a cyclic AMP-independent cytosolic 80000 Da protein designated fl-adrenergic receptor kinase. An early event in this process is the translocation of fl-adrenergic receptor kinase from the cytosol to the plasma membrane . In a manner akin to rhodopsin kinase, which phosphorylates only the photoactivated form of rhodopsin, ,-adrenergic receptor kinase was shown to phosphorylate multiple serine and threonine residues (up to 9 mol of phosphate/mol of receptor) on only the agonist-occupied form of the receptor .
Removal of the C-terminus of reconstituted hamster lung /2-adrenergic receptors by carboxypeptidase Y treatment removed most, but not all, of the phosphorylation sites, suggesting that this serine-threonine-rich region is the major site of receptor regulation by phosphorylation (Dohlman et al., 1987) . The similarity of the two systems is further demonstrated by the fact that in cell-free systems fl-adrenergic receptor kinase can utilize rhodopsin as a substrate (Mayor et al., 1987) .
The /2-adrenergic receptor is also a substrate of cyclic AMPdependent protein kinase A, suggesting a feedback mechanism of receptor desensitization based on activation of adenylate cyclase . There are two sites on the fi2-adrenergic receptor, at positions 259-262 on the third cytoplasmic loop and positions 343-348 on the C-terminus, which contain the Lys/ArgArg-X-(Xaa)-Ser-consensus sequence that is thought to serve as a site for protein kinase A phosphorylation (Dixon et al., 1986 (Benovic et al., 1987a,b) .
To test whether phosphorylation of the protein kinase A consensus sites and/or the ,-adrenergic receptor kinase sites (i.e. the serines and threonines of the C-terminus) results in an uncoupling of the /?2-adrenergic receptor, a series of mutations altering these putative phosphorylation domains were created; the ability of these mutant receptors to undergo desensitization was then studied (Bouvier et al., 1988; Hausdorff et al., 1989) . Phosphorylation of different domains of the human /82-adrenergic receptor was associated with different densensitization phenomena (Hausdorff et al., 1989 (Bouvier et al., 1988) . Two mutants of the human /32-adrenergic receptor that lack /8-adrenergic receptor kinase phosphorylation sites, one truncated after amino acid 365 (i.e. missing the serine/threonine-rich portion of the C-terminus), and one in which 11 serine and threonine residues within the C-terminus were substituted with either alanine or glycine, were examined for their ability to undergo desensitization under these same conditions. Both displayed a short-term (i.e. within 15 min after addition of agonist) delay in the onset of desensitization. However, after 180 min of exposure to isoprenaline, both mutant receptors were maximally desensitized. In this system, early desensitization events were agonist-specific, i.e. homologous desensitization, with other desensitization mechanisms (e.g. heterologous) being activated at longer agonist exposure times. These data implied that ,-adrenergic receptor kinase phosphorylation is, at least in part, responsible for early-onset homologous desensitization, but has little or no role in the later events (Bouvier et al., 1988) . Recent evidence has also linked receptor phosphorylation with heterologous desensitization of the /32-adrenergic receptor. A system has been described in which the hamster /?2-adrenergic receptor expressed in L cells undergoes heterologous desensitization in response to short (< 10 min) exposure to relatively low (10-50 nM) concentrations of adrenaline or of another activator of adenylate cyclase, prostaglandin E1 (PGE1); this heterologous desensitization is characterized by a 2-3-fold increase in the Kact of adrenaline for adenylate cyclase stimulation without receptor sequestration, or a loss of maximal efficacy for adenylate cyclase activation (Clark et al., 1989) . In cells expressing a deletion mutant lacking residues corresponding to the consensus site for protein kinase A phosphorylation on the third cytoplasmic loop (i.e. residues 259-262), exposure to either adrenaline or PGE1 did not produce desensitization. Cells expressing a /?2-adrenergic receptor deletion mutant that lacks the other consensus site for protein kinase A phosphorylation, i.e. residues 343-348 in the C-terminus, or one in which the serine-rich C-terminus has been removed by a truncation mutation at residue 354, displayed normal heterologous desensitization in response to prior adrenaline or PGE1 exposure. These findings indicate that phosphorylation of the consensus site at residues 259-262 on the third cytoplasmic loop by protein kinase A is necessary for heterologous desensitization in this system (Clark et al., 1989 As an alternative to the phosphorylation hypothesis, it has been suggested that the regions of the ,/2-adrenergic receptor that appear to be necessary for activation of G. are also necessary for receptor sequestration. A series of hamster f82-adrenergic receptors with deletions in the third cytoplasmic loop were studied for their ability to activate G. and adenylate cyclase and to undergo sequestration. The only two mutant receptors that did not undergo sequestration in desensitization studies on transfected L cells, del-239-272 and del-222-229, were completely unable to activate Gs or adenylate cyclase (see earlier) (Strader et al., 1987c; Cheung et al., 1989) . Deletion mutants such as del-230-262 that could partially stimulate adenylate cyclase underwent significant, although less than maximal, sequestration. Based on these findings, it was postulated that the same structural features of the receptor responsible for G protein coupling are also involved in the sequestration process. However, in a subsequent study, these investigators found that coupling to G.
was not required for sequestration of f82-adrenergic receptors. Replacement of residues 222-229 of the hamster /32-adrenergic receptor with the analogous region of the human ml muscarinic acetylcholine receptor yielded a hybrid receptor that was unable to trigger Gs activation (as measured by an inability to cause a rightward shift in isoprenaline competitive binding curves in the presence of guanosine 5'-[fl,y-imido]triphosphate) or stimulate adenylate cyclase; nevertheless, this altered receptor underwent nearly normal isoprenaline-mediated sequestration ). Thus at the present time the structure(s) within the /,-adrenergic receptor which are responsible for sequestration have not been defined.
Finally, there is some evidence that agonist-induced receptor phosphorylation may play a limited role in the down-regulation of ,l-adrenergic receptors. Bouvier et al. (1989) discovered that when CHW cells expressing wild-type human fl2-adrenergic receptors are treated with dibutyryl cyclic AMP there is a gradual loss of total receptor number over the course of 24 h. Only a negligible amount of receptor sequestration is induced by this treatment. The onset of receptor down-regulation is delayed, however, in cells expressing mutant fl2-adrenergic receptors whose protein kinase A consensus sites were disrupted by insertion or substitution. It was suggested that phosphorylation of the receptor might increase the rate of down-regulation, at least in the initial few hours after dibutyryl cyclic AMP exposure, perhaps by enhancing the susceptibility of the receptor to proteases. However, the major mechanism by which dibutyryl cyclic AMP causes the long-term down-regulation of the wildtype receptor is by inducing a decrease in the steady-state levels of fl2-adrenergic receptor mRNA; this is not altered in cells expressing the mutant receptor. It therefore appears that, at least over the long term, the process of cyclic AMP-mediated down-regulation occurs independently of receptor phosphorylation .
In all likelihood, other mechanisms ancillary to or independent of receptor phosphorylation may play a role in agonist-induced desensitization. It was shown that the uncoupling of the/2-adrenergic receptor from G. in a reconstituted phospholipid vesicle induced by treatment with 8-adrenergic receptor kinase could be enhanced by the addition of the retinal-derived protein, arrestin (Benovic et al., 1987a) . Recently, a cDNA clone encoding a protein homologous to arrestin was isolated. This protein, termed /,-arrestin, was found to inhibit the activity of phosphorylated /3-adrenergic receptors by more than 75 %, but to not affect that of rhodopsin (Lohse et al., 1990) . These findings suggest that /3-adrenergic receptor kinase and /3-arrestin may functio n in conc ert to mediate homologous desensitization of /3-adrenergic receptors (Lohse et at., 1990) .
Other domains and/or amino acid residues may also influence receptor down-regulation. Valiquette et al. (1990) have obtained evidence that two tyrosine residues in the C-terminus of the human /32-adrenergic receptor, Tyr350 and Tyr354, play some role in the ability of this receptor to undergo down-regulation. These investigators found that conversion of both of these residues to alanine produces a mutant /82-adrenergic receptor that is less susceptible to the effects of prolonged (up to 24 h) isoprenaline exposure relative to wild-type receptors when expressed in CHW cells. These mutations do not prevent the receptor from undergoing normal sequestration, however. It was speculated that these tyrosine residues may be important for interactions with proteins involved in endocytosis, such as those involved in the formation of clathrin-coated vesicles. This is based on studies with non-G-protein-linked membrane receptors, such as the mannose 6-phosphate receptor, whose C-terminal tyrosines appear to be necessary for agonist-induced endocytosis involving clathrin-coated vesicles (Lobel et al., 1989) . The role of clathrincoated vesicles in the down-regulation of G protein-linked receptors has yet to be thoroughly examined.
PROSPECTUS
What are the archetypal features shared by all G proteincoupled receptors? In the 9 years since the report of the molecular cloning of the first G protein receptor, more than 100 distinct receptor subtypes of this large gene family have been sequenced, permitting us to identify and begin to examine the role of common structural motifs. In this review we have catalogued some of the commonalities among these receptors. It is debatable whether any of these features other than the presence of seven transmembrane domains constitute a sine qua non for G proteincoupled receptors: exceptions have already been found for many of these motifs. Such exceptions are not surprising, given the large number of members of this gene family and the diversity of physiological functions that these receptors modulate. Nevertheless, collectively these features establish a kinship between these specialized proteins and point to a common ancestry. Ultimately, one of the major goals of structure-function studies of receptors is to identify the features that distinguish one receptor subtype from another. In vitro mutagenesis will likely serve as an important tool in this process. Understanding receptor diversity at the molecular level constitutes a major goal of receptor research, as it would provide the framework for the design of subtype-specific pharmacological agents.
Since this review was originally submitted, the cloning and sequence analysis of the secretin (Ishihara et al., 1991) , parathyroid hormone (Juppner etal., 1991) and calcitonin (Lin etal., 1991) receptors has suggested the existence of a new subfamily of G protein-linked receptors. This family of receptors contains seven potential transmembrane domains, but shows no sequence similarity with other reported G protein-coupled receptors.
